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Background: Decoy receptor 3 (DcR3), a decoy receptor against Fas ligand belonging to the
tumor necrosis factor receptor superfamily, is overexpressed in some forms of cancer. It
was recently reported that DcR3 could protect endothelial cells from apoptosis, implying a
potential role in the development of vessels, whereas its role in the lymphangiogenesis
remains unclear. In the present study, we studied the DcR3 expression and its relationship
with the lymphatic microvessel density (LMVD) to investigate if it played a role in the
lymph metastasis of human breast cancer.
Materials and methods: Real-time polymerase chain reaction and immunohistochemistry
were performed tomeasure themessenger RNA and protein expression of DcR3 in the breast
cancer tissues, noncancerous counterparts, and axillary lymph node from 63 patients. LMVD
in these specimens was assessed by counting the D2-40 labeledemicrovessels. Furthermore,
the correlations between DcR3 expression and LMVD and other clinicopathologic parameters
were analyzed.
Results: DcR3 was overexpressed in the breast cancer tissue of 58 patients (92.1%) and was
also expressed in vascular endothelial cells and tumor cells in the lymph nodes. LMVD in
cancer tissue and lymph nodes were both positively correlated to the aberrant expression
of DcR3.
Conclusions: The relevance between DcR3 overexpression and LMVD revealed the existence
of possible links between DcR3 and lymphangiogenesis. Based on these findings, it is
important to further explore the regulation of lymphangiogenesis operated by the reverse
tumor necrosis factor signaling of DcR3.
ª 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.1. Introduction off the signal via decoy receptors (DcRs). DcR3, secreted as aIt is well known that resistance to apoptosis is an important
feature of tumor cells, which favors proliferation and en-
hances their immune escape. One of the smartest ways
known to inhibit death ligandeinduced apoptosis is to switchter, the First Affiliated H
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factor (TNF) receptor superfamily [1,2]. It recognizes three
TNF-superfamily members, such as Fas ligand (FasL/CD95L/
TNFSF6) [1], LIGHT (TNFSF14) [2], and TNF-like molecule
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against FasL-induced apoptotic cell death and chemotaxis and
protects tumor cells from immune surveillance by neutrali-
zation of LIGHT-mediated tumor apoptosis and T-cell stimu-
lation [4,5]. Moreover, it neutralizes TL1A, the angiostatic
factor in endothelial cells, thus, induces angiogenesis [6,7].
DcR3 overexpression has been observed in various malignant
tumors arising from esophagus, stomach, glioma, lung, colon,
and rectum [1,8e12] and was found to correlate with local
lymph node and systemic metastasis [12]. Because regional
lymph node metastasis is one of the most important prog-
nostic parameters for cancer patients, DcR3 was considered to
be a useful biomarker in some types of cancers [11,13].
Breast cancer was reported to be the most frequently
diagnosed cancer and the leading cause of cancer death
among female accounting for almost a quarter of the total
cancer cases in the developing countries [14]. Metastasis or
recurrence happens in approximately 30% of breast cancer
patients despite the advances in early detection and under-
standing of the molecular bases of tumor biology. Lymphatic
metastasis is known as a direct approach in dissemination
for breast cancer cells because lymphatic microvessel is
constituted of unilaminar and discontinuous basement
membrane while lacking tight interendothelial junctions
[15,16]. Furthermore,mounting clinical and experimental data
suggest that tumor cells facilitated lymphatic metastasis by
selecting lymphangiogenic factors and promoting the gener-
ation of new lymphatic vessels from preexisting lymphatics
[17,18] or lymphatic endothelial progenitors [19].
Recently, it was found that DcR3 could induce a proan-
giogenic phenotype by deceiving binding to TL1A in human
endothelial cells [7], while whether it plays a role in the gen-
eration of lymphmicrovessels or tumor lymphangiogenesis is
still unknown. The goal of this study was to investigate
whether DcR3 is relevant to lymphangiogenesis and whether
this protein could be used as a biomarker predicting lymphatic
metastasis in breast cancer. We will use the lymphatic
microvessel density (LMVD) in the slides of specimens to
assess the number of lymph vessels, detect the gene and
protein expression of DcR3 in breast cancer tissue, noncan-
cerous counterparts, and matched lymph node from 63 pa-
tients and evaluate their relationship with clinicopathologic
parameters.2. Materials and methods
2.1. Patients and specimens
This study was in compliance with the Helsinki Declaration
and approved by the Institutional Research Board at Xiamen
University. Written informed consent was obtained from all
patients. Institutional Ethics Committee approval for this
project was provided before the commencement of the study.
A total of 189 samples were obtained from 63 randomly
selected female patients who underwent mastectomy at the
First Affiliated Hospital of Xiamen University from February
2009 to February 2011. Each patient contributed three types
of specimen, including breast cancer tissue, noncancerous
counterparts (located more than 5 cm away from the tumormargins) and one of the suspicious metastatic lymph nodes
from the same side of the armpit. Each specimen was micro-
dissected immediately after mastectomy and divided into two
parts: one part was snap-frozen in liquid nitrogen and the
other was fixed for immunostaining. Patients withmetastases
breast cancer or who had received preoperative treatment,
including radiotherapy or chemotherapy, were excluded.
Histologic type, tumor size, and histologic grade of tumors
were evaluated by routine pathologic examination. The status
of lymph node metastasis, estrogen receptor (ER), progester-
one receptor (PR), and human epidermal growth factor re-
ceptor 2 (HER-2/neu) score were evaluated according to the
American Joint Committee on Cancer (seventh edition).
2.2. Real-time polymerase chain reaction
Total RNA was extracted from frozen materials by Trizol re-
agent according to the manufacturer’s protocol (Invitrogen).
Reverse transcription of total RNA into complementary DNA
was conducted using TaKaRa Reverse Transcription Reagents
(Takara Bio Inc, Japan) at 37C for 15 min followed by 85C for
5 sec. Primers were designed using Primer Premier 5.0 software
(Premier, Canada) and synthesized by Invitrogen. DcR3
messenger RNA(mRNA) sequenceespecific primers used (Gen-
BankAccessionNo. NM032945.2)were the following sequences:
forward: 50-CACGCTGGTTTCTGCTTGGA-30; and reverse: 50-
CGATGACGGCACGCTCACA-30. The house-keeping gene glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was
used as a reference: forward: 50-GAAGGTGAAGGTCGGAGTC-30;
reverse: 50-GAAGATGGTGATGGGATTTC-30. Real-time quanti-
tative polymerase chain reaction was performed using the
Takara SYBRR Premix Ex Taq II PCR kit (Takara Bio Inc) in
a Roche Lightcycler 480 instrument (Roche, Switzerland).
Reactions were performed in 10 mL volumes with denaturation
at 95C for 5 sec, annealing at 58C for 15 sec, and extension at
72C for 20 sec, more than 40 cycles. To determine the fold
change in expression and to normalize DcR3 expression level,
triplicates of cycle threshold for the target gene were averaged
and divided by the average of the triplicate obtained from
glyceraldehyde 3-phosphate dehydrogenase in the same
specimen.
2.3. Immunohistochemistry staining and evaluation
Sections of formalin-fixed, paraffin-embedded tissues were
deparaffinized, stepwise rehydrated, and the endogenous
peroxide was blocked. For D2-40 staining, slides were pro-
cessed with antigen retrieval by boiling the slides in citrate
buffer (pH 6.0) for 1.5 min. For DcR3 staining, slides were
boiled in an ethylene diamine tetraacetic acid solution for
20 min. Nonspecific binding was blocked using 10% nonim-
mune goat serum (Santa Cruz) for 10 min. Sections were then
incubated for 120 min at room temperature with anti-DcR3
antibody (clone SC-05; Abcam, UK) at a 1: 350 dilution or
with D2-40 antibody (clone D2-40; Abcam) at a 1:40 dilution.
After rinsing and incubating in the second antibody, sections
were incubated with the EnVision Detection System (Dako,
Denmark), counterstainedwith hematoxylin, dehydrated, and
mounted. Negative controls were processed using the same
procedure, except that 10% nonimmunemouseerabbit serum
Fig. 1 e LMVD (the number of lymphatic microvessels) is elevated in breast cancer tissue and axillary lymph node with
metastasis. (A and B) Representative images of tumor tissue: (A) intratumoral lymphatic vessel is inflated with irregular cell
walls; (B) peritumoral lymphatic vessels surrounded tumor sites, which are not stained. (C and D) Representative images of
axillary lymph nodes: (C) the box shows the “hot spot”; (D) the magnified “hot spot” in (C). Asterisks represent where tumor
cells are. Arrow heads indicate lymphatic microvessels labeled with D2-40 by IHC (EnVision). (E) LMVD increased by
approximately 6-fold (P＜ 0.001) in tumor tissue (T), comparedwith the noncancerous counterparts (N). (F) In the axillary node
withmetastasis (LN＋), LMVD increased by approximately 3-fold (P< 0.01), comparedwith the nodewithoutmetastasis (LNL).
(Color version of figure is available online.)
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detectable staining was observed in any of the negative con-
trol slides.
Immunohistochemical morphometric analyses were esti-
mated independently by two authors who had no prior
knowledge of the patients’ clinicopathologic data. LMVD was
evaluated by counting the number of immunostained vessels
labeled with D2-40 on slides. As reported previously [20], we
first identified the area containing the most stained vessels
(“hot spot”) by scanning the sections at low magnification
(100), then counted the number of positive stained vessels in
two highmagnification fields (200) as shown in Figure 1C and
D. We defined those vessels as lymphatics if they were lined
by a single layer of immunopositive flattened endothelial cells
with a vascular lumen without erythrocytes inside [21]. LMVD
in tumor sections was determined by averaging the number
of total lymphatic vessels in the “hot spot,” including in-
tratumoral lymphatic vessels and peritumoral ones. Suchrepresentative images were shown in Figure 1A and B. Then
the mean LMVD was calculated as the average of four counts
(two microscopic fields from each of the two authors). When
any discrepancy >10% of the microvessels happened, discor-
dant cases were recounted.
Results of DcR3 immunohistochemistry (IHC) staining
were determined according to Wu study [22]. The percentage
of cell staining was shown on a graduated percentage (0%e
100%): (þ) represented that 10%e30% of cells were positive
staining; (þþ) represented that 30%e60% of cells were posi-
tive; (þþþ) represented that 60%e100% of cells were positive.
For analysis as a dichotomous variable, sections with <10% of
stained cells were classified as negative staining of DcR3.
2.4. Statistics
SPSS (version 17.0; SPSS Inc, Chicago) software was used.
Data, which were normally distributed, were expressed as
Table 1 e Correlation between DcR3 expression, LMVD, and clinicopathologic parameters.
Clinicopathologic parameters N DcR3 protein P DcR3 mRNA P LMVD (per 200 field) P
 þ
Age (y) 1.000 0.268 0.691
<60 45 4 41 4.02  1.41 13.67  2.18
60 18 1 17 7.17  2.67 11.00  2.59
Histologic grade* 0.648 0.555 0.156
I þ II 26 3 23 5.72  2.04 9.75  2.15
III þ IV 32 2 30 4.75  2.04 16.30  2.90
Tumor size 0.609 0.127 0.483
T1 22 1 21 5.44  2.07 8.73  1.09
T2 35 3 32 2.88  0.55 16.22  2.82
T3 6 1 5 23.29  16.5 9.00  4.04
Axillary nodal involved 0.900 0.775 0.408
N0 33 3 30 6.61  2.23 11.05  1.97
N1 18 1 17 2.54  0.70 15.75  3.81
N2 9 1 8 3.67  1.88 17.40  6.49
N3 3 0 3 3.79  3.24 6.00  2.00
Estrogen receptor status 0.083 0.881 0.287
 15 3 12 6.23  4.21 14.50  3.18
þw þþþ 48 2 46 4.52  1.10 12.45  2.07
Progesterone receptor 0.055 0.621 0.217
 13 3 10 8.23  5.35 16.75  4.01
þw þþþ 50 2 48 4.19  1.03 12.03  1.02
HER-2/neu score 0.649 0.318 0.244
(0e1) 20 2 18 3.81  1.67 11.54  3.40
þ(2e3) 43 3 40 5.46  1.71 13.61  2.02
“þ”, “þþ,” and “þþþ” for DcR3 immunochemistry staining was all grouped together as “þ.”
* Only indicating the 58 patients with invasive ductal breast cancer.
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performed using Spearman correlation test to analyze the rank
data andManneWhitney U-test to differentiate nonparametric
means of different groups. Chi-square test, Yates’ correction, or
Fisher’s exact test was used to analyze qualitative independent
variables. All statistical tests were two sided. P value <0.05 was
considered statistically significant.3. Results
3.1. LMVD assessment
D2-40 positive stainings were primarily detected in the cyto-
plasm andmembrane of lymphatic endothelial cells, whereas
not in the tumor cells or the blood vessel endothelial cells
(Fig. 1). The average LMVD in the breast cancer tissue from the
63 patients was 13.25  1.75 (range 1.17e42.83) lymphatic
microvessels per 200 field (LMV per 200 field). The LMVD inTable 2 e DcR3 mRNA and protein expression in breast cancer
Tissue type DcR3 mRNA U Stai

Tumor specimen 4.910  1.262 5
Noncancerous tissue 1.347  0.237 435.0** 29
“þ”, “þþ,” and “þþþ” for DcR3 immunochemistry staining are grouped t
**P < 0.01 and ***P < 0.001 are considered statistically significant.the noncancerous counterparts was 2.28  0.18 (range
1.00e5.73) LMV per 200 field. Thus, the LMVD was signifi-
cantly different between the cancer tissue and the counter-
parts (ManneWhitney test, P < 0.001; Fig. 1E). Furthermore,
according to that whether the axillary lymph node had
metastasis, patients were divided into two groups: metastatic
(30 cases) and nonmetastatic (33 cases). We found that the
LMVD in the axillary node with metastasis was greater than
that without metastasis (ManneWhitney test, P ¼ 0.005;
Fig. 1F). Then the relevance between LMVD and the clinico-
pathologic characteristics was also evaluated. However, the
LMVD was not correlated with patients’ age, histologic grade,
tumor size, axillary lymph node involvement, ER or PR status,
or Her-2/neu score (P > 0.05, respectively; Table 1).3.2. DcR3 expression
As shown in Table 2, the DcR3mRNA expression was elevated
approximately four times in the cancer tissue compared withand the noncancerous counterparts.
ning grades of DcR3 Positive rate (%) c2
þ þþ þþþ
24 25 9 92.1
25 7 2 54.0 31.54***
ogether as “þ.”
Fig. 2 e Representative IHC staining of DcR3 (EnVision). (AeC) breast cancer tissue, (D) the noncancerous counterparts, (E)
lymph node without metastasis, (F) lymph node with metastasis. (D) and (E) negative for DcR3 staining, (A) and (F) ＋ for
DcR3 staining, (B) ＋＋ for DcR3 staining, (C) ＋＋＋ for DcR3 staining. Asterisks represent the areas where tumor cells are;
Long arrow heads indicate the vessel-like structure, which was detected by DcR3 in lymph node. (Color version of figure is
available online.)
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quency of DcR3 protein expression in cancer tissue was 92.1%
(58 of 63 surgical specimens), which was significantly greater
than that in the noncancerous counterparts (54.0%, 34/63;
c2 ¼ 31.54, P < 0.001; Table 2).
As presented in Figure 2AeD, DcR3 positive staining was
observed in the tumor nest with faint or even no staining in
the surrounding matrix. Besides, in the axillary lymph node,
DcR3 was specifically expressed on some endothelial cells,
which were arranged like a vesselelumen structure among
lymphatic cells (Fig. 2E and F). When performed IHC staining
using either DcR3 or D2-40 antibodies on the serial sections,
we found that the endothelial cells which were labeled by
DcR3 had negative staining of D2-40 in the matched region of
the serial sections (Fig. 3C,D,H, and G), suggesting that the
vessel-like structure specifically labeled with DcR3 in lymph
node was the bloodmicrovessel, which did not express D2-40.
To avoid the interference by blood vessel with the results of
DcR3 staining in lymph node, the staining of endothelial cells
was excluded when assessing the protein expression level in
lymph node.3.3. Aberrant expression of DcR3 is associated with
LMVD
As showed in the representative images in Figure 3, the tumor
specimen with DcR3 overexpression had higher LMVD. The
LMVDwas significantly different between breast cancers with
and without DcR3 expression (ManneWhitney test, P < 0.05;
Fig. 3I); and similarly, the lymph node with DcR3 expression
had greater LMVD than that without DcR3 expression (Man-
neWhitney test, P < 0.05; Fig. 3K). A positive correlation was
further established between DcR3 expression and LMVD in
both breast cancer tissue and lymph node (Spearman corre-
lation coefficient 0.326 and 0.399, respectively). No significantcorrelations were observed between DcR3 expression and
patients’ age, histologic grade, tumor size, axillary node
involvement, ER or PR status, or Her-2/neu score, however
(P > 0.05; Table 1).4. Discussion
Increasing evidence has shown that DcR3, a decoy receptor
belonging to the TNF receptor superfamily, suppressed
endothelial cell apoptosis by inhibiting the TL1A-death re-
ceptor 3 interaction [7,23], while whether it also plays a role in
the lymphangiogenesis is still unknown. In this study, we
demonstrated a positive correlation between DcR3 expression
and LMVD, not only in breast cancer tissue but also in lymph
node, thus provided a new insight into the relationship be-
tween DcR3 and lymphangiogenesis. It is possible that the
aberrant expression of DcR3 triggers “reverse signaling” for
endothelial cell survival, thus facilitates lymphangiogenesis
and further lymphatic metastasis for tumor cells.
LMVD is the measurement of lymphatic microvessel
growth in and around a tumor and is frequently used as a
clinical indicator of lymphangiogenesis [24]. In the present
study, LMVD was elevated in breast cancer tissue compared
with its noncancerous counterparts, supporting the opinion
that tumor cells foster a favorite microenvironment for
growth and metastasis by facilitating lymphangiogenesis.
Increased LMVD was associated with increasing incidence of
metastasis in breast cancer patients [25]. It is unsurprised that
the booming lymphatic microvessels create more opportu-
nities for tumor cells to spread. Previous studies showed
that lymphangiogenic growth factors derived from primary
tumoreinduced lymphangiogenesis in sentinel lymph node
before the first arrival of metastatic cells [26], suggesting that
tumor cells prepared the “soil” in lymph node beforehand to
Fig. 3 e DcR3 overexpression is correlated to higher LMVD (EnVision) in tumor tissue and lymph node. (AeD) Representative
IHC staining of DcR3, (A) negative for DcR3 staining, (B) and (C) ＋＋ for DcR3 staining, (D) ＋ for DcR3 staining; (EeH)
representative images of lymphatic microvessels labeled by D2-40. (A and E), (B and F), (C and G), and (D and H) represent the
same specimen, respectively; (A), (B), (E), and (F) are breast cancer tissue; (C), (D), (G), and (H) are axillary lymph nodes.
Asterisks represent the areas where tumor cells are. (D and H) respectively show the magnified “hot spot” in (C and G). Long
arrow heads indicate the vessel-like structure which was labeled by DcR3 in lymph node. (I) and (K) LMVD in the tumor
tissue and lymph node with DcR3 positive expression (DcR3＋) are greater than that in the corresponding tissue without
DcR3 expression (DcR3e) (P< 0.05, respectively). (J) Difference in LMVD in the noncancerous counterparts between these
two groups is not statistically significant, however (P> 0.05). (Color version of figure is available online.)
j o u r n a l o f s u r g i c a l r e s e a r c h 1 8 8 ( 2 0 1 4 ) 4 5 9e4 6 5464render the microenvironment more hospitable for secondary
tumor formation [27].
Several clinical studies reported that elevated DcR3 protein
expression in tumor specimen was positively correlated with
high-grade of tumor or the incidence of lymph node metas-
tasis, including esophageal cancer [28], renal cell cancer [13]
and gastric cancer [11]. We found here that the mRNA and
protein expression of DcR3 were both elevated in the human
breast cancer tissue, and the aberrant expression of DcR3 was
closely correlated to the number of lymphatic microvessels,
indicating that DcR3 had a close relationship with tumor
infiltration and lymphatic metastasis. Thus, it is reasonable to
speculate that as a lymphangiogenic factor secreted by tumor
cells, DcR3 might be used as a molecular marker predicting
the potential of tumor invasion and metastasis. Certainly,
intensive study is needed.
Previous studies showed that DcR3 was overexpressed in
various malignant tumors [1,8e13,28], whereas rare studies
focused on the DcR3 expression pattern in normal human
lymph nodes. Bai et al. [8] found that the DcR3 mRNA was
expressed at a low level in normal lymph node, whereas theydid not detect the protein expression further. To the best of
our knowledge, our work is the first study that demonstrates
the vessel-like structure detected by DcR3 in lymph node
is the bloodmicrovessel rather than the lymphmicrovessel. It
is known that TL1A, a ligand for DcR3, is predominantly
expressed in endothelial cells and functions as an autocrine
cytokine, inhibiting angiogenesis, cell proliferation, and
tumor growth [29]. As a soluble molecular, DcR3 fraudulently
bound to TL1A and trapped on endothelial cells, which might
act as an angiogenic factor via blocking the negative regulator
TL1A [7]. From this aspect, DcR3 may serve as a biomarker of
blood vessel in lymph node.5. Conclusions
We found here that DcR3 was aberrantly overexpressed
in human breast cancer tissue. In addition to tumor cells,
the protein expression was also detected specific in blood
vessels in the axillary lymph node. LMVD was elevated in the
cancer tissue and lymph node with metastasis. The relevance
j o u r n a l o f s u r g i c a l r e s e a r c h 1 8 8 ( 2 0 1 4 ) 4 5 9e4 6 5 465between DcR3 expression and LMVD reveals that DcR3 is
closely related to the lymphangiogenesis. Based on these
findings, it is promising for us to further explore the possible
regulation of lymphangiogenesis operated by the reverse TNF
signaling of DcR3.
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